Recent Articles
At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated
At the Federal Summit on Psychedelic Medicine, policymakers, researchers, clinicians, and veterans advocates spent a day working through the real implementation challenges facing the field from REMS and rescheduling to ARPA-H’s $139 million EVIDENT initiative and the ethics of informed consent.
By Joe Moore
Filter
No Promises and No Goals
In this excerpt from Radical Adventure, Andrew Feldmár challenges the medicalization of psychedelic psychotherapy and…
By Andrew Feldmár
Why Ketamine Is Changing Psychiatry
Scott Shannon, MD argues that ketamine is doing more than relieving depression. It may be…
By Scott Shannon, MD – Wholeness Center, Fort Collins, Colorado
Whitehouse Directs FDA, HHS and VA to Expand Psychedelic Research Pathways
The White House moved to accelerate federal handling of psychedelic drugs, including ibogaine, while leaving…
By Joe Moore
Op-Ed: Iboga, Ibogaine & 5-MeO-DMT: What gets missed when complex medicines are reduced to standard protocols
What gets lost when iboga is reduced to ibogaine, and complex care is reduced to…
By Paije West and Fletcher Burdick
A Practitioner Statement on the Responsible Development of Ibogaine in the United States – Open Letter
Dear Colleagues,We write as a collective of practitioners, researchers, clinicians, and integration specialists with direct,…
The Place of Incilius Alvarius Within Indigenous Society
A look at Sonoran Desert toad medicine through the lens of indigenous sovereignty, ecological strain,…